KREBS BIOCHEMICALS & INDUSTRIES LTD.-$

Krebs Biochemicals & Industries Ltd has announced its 34th Annual General Meeting (AGM) will be held on September 29, 2026, at 11:30 a.m. via Video Conferencing/Other Audio Visual Means (VC/OAVM). The company has dispatched the Notice of the 34th AGM along with the Annual Report for FY 2025-26 to its shareholders. The Annual Report is also available on the company's website and stock exchange platforms. The company is providing e-voting facilities for members, with remote e-voting commencing on September 25, 2026, and concluding on September 28, 2026. The cut-off date for determining voting eligibility is September 23, 2026.

Krebs Biochemicals & Industries Ltd has filed its Annual Report for the financial year ended March 31, 2026. The report includes a five-year highlight of key financial metrics. For FY26, the company reported Total Income of ₹2,575.79 Lakhs, a Profit/(Loss) Before Tax of ₹(1,693.31) Lakhs, and a Profit/(Loss) After Tax of ₹(1,693.31) Lakhs. Reserves and Surplus stood at ₹(18,431.53) Lakhs, leading to a Net Worth of ₹(16,275.47) Lakhs. Earnings Per Share (EPS) was ₹(85) and Book Value Per Share was ₹(75.49). The report also details corporate information, directors, key managerial personnel, registered office, plant locations, and statutory auditors.

Krebs Biochemicals & Industries Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a net loss of ₹248.48 lakhs for the quarter. Revenue from operations stood at ₹1,038.80 lakhs. The company's board also approved the amalgamation of Krebs Biochemicals with Ipca Laboratories Limited, with an appointed date of April 1, 2026. The Vizag manufacturing unit remains closed due to a Pollution Control Board order.

Krebs Biochemicals & Industries Ltd announced the outcome of its Board Meeting held on August 6, 2026. The board approved and took on record the unaudited financial results for the first quarter ended June 30, 2026, along with the Limited Review Report by the auditors. The company's manufacturing unit in Vizag remains closed following an order from the Andhra Pradesh Pollution Control Board. The board also approved the amalgamation of Krebs Biochemicals with Ipca Laboratories Limited, with an appointed date of April 1, 2026.

Krebs Biochemicals & Industries Ltd has announced that its Board of Directors will convene on August 6, 2026. The primary agenda item is to consider and approve the unaudited financial results for the first quarter ended June 30, 2026. Concurrently, the company reaffirmed its trading window closure for insiders, which began on June 30, 2026, and will remain shut until 48 hours post the declaration of these financial results, as per SEBI regulations.

Krebs Biochemicals & Industries Ltd announced that its Board of Directors has approved a Scheme of Amalgamation with Ipca Laboratories Limited. The merger, subject to regulatory approvals, is set to take effect from April 1, 2026. The rationale includes achieving operational synergies, cost optimization, and consolidating businesses. Krebs Biochemicals, which has incurred continuous losses, possesses manufacturing capabilities for fermentation-based APIs that Ipca Laboratories lacks, potentially enabling Ipca to develop new APIs and secure supply chains for key intermediates. The transaction is considered a related party transaction but will be conducted at arm's length. No cash consideration will be paid; Ipca will issue 7 equity shares for every 200 shares of Krebs Biochemicals.

Krebs Biochemicals & Industries Ltd announced that its Board of Directors has approved a Scheme of Amalgamation with Ipca Laboratories Limited. The merger, subject to regulatory approvals, is set to take place under Sections 230-232 of the Companies Act, 2013. The appointed date for the scheme is April 1, 2026. The rationale includes achieving operational synergies, cost optimization, consolidation of business, and leveraging Krebs' fermentation-based API manufacturing capabilities. Ipca Laboratories reported a standalone audited total income of ₹7431 Crores for FY26, while Krebs Biochemicals had an income of ₹26 Crores, primarily from conversion charges. The transaction is considered a related party transaction but will be conducted at arm's length. There will be no cash consideration; instead, Ipca Laboratories will issue 7 equity shares for every 200 shares of Krebs Biochemicals.

Krebs Biochemicals & Industries Ltd has announced the closure of its trading window for the quarter ended June 30, 2026. This closure, effective from the close of business hours on June 30, 2026, is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut until 48 hours after the declaration of the unaudited financial results for the first quarter. The specific date for the Board meeting to consider these results will be communicated separately to the stock exchanges.

Krebs Biochemicals & Industries Ltd reported audited financial results for the year ended March 31, 2026. The Board of Directors approved the results at a meeting held on May 21, 2026. Revenue from Operations stood at ₹2,373.16 lacs, while the company reported a loss before tax of ₹1,693.31 lacs. The Statutory Auditors issued an unmodified report on the financial statements. The Vizag manufacturing unit remains closed following an order from the Andhra Pradesh Pollution Control Board.

Krebs Biochemicals & Industries Ltd's board meeting on May 21, 2026, approved the audited financial results for the year ended March 31, 2026. The company reported a net loss before tax of ₹1,693.31 lacs for the year ended March 31, 2026, compared to a loss of ₹2,692.40 lacs in the previous year. Revenue from operations stood at ₹2,373.16 lacs, down from ₹4,331.19 lacs in the previous year. The meeting commenced at 11:30 am and concluded at 1:20 pm.